Nine out of 10 responding rheumatologists stated the test would increase their confidence when making prescribing decisions WALTHAM, Mass. – DECEMBER 7, 2020Scipher Medicine, a precision immunology company matching patients with the most effective therapy, today...
PrismRA® first-of-its-kind molecular signature test validated in Ambry’s central laboratory.Partnership provides infrastructure for rapid scaling and patient accessibility. SEPTEMBER 17, 2020- WALTHAM, MA, and ALISO VIEJO, CA – Scipher Medicine, a precision...
— Companies to jointly validate novel drug targets —- Scipher eligible for upfront, opt-in and milestone payments —- Galapagos to progress selected targets into drug discovery — Mechelen, Belgium and Boston, USA; 12 August 2020 –...
PrismRA identifies patients 6.6 times less likely to respond to TNFi therapy JULY 28, 2020- WALTHAM, MA- (Business Wire)- Scipher Medicine, a precision immunology company that helps match patients with their most effective therapy, today announced successful results...
Appoints Slava Akmaev, Ph.D., as Chief Technology Officer WALTHAM, Mass.–(BUSINESS WIRE)–Scipher Medicine, developer of a molecular technology platform used to ensure patients are prescribed most effective therapy, today announces the addition of Slava...
Investment to Accelerate Molecular Diagnostic Product Selection, Development and Accessibility WALTHAM (February 19, 2020) — Scipher Medicine, a developer of a molecular technology platform used to ensure patients are prescribed the most effective therapy, announced...
